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1 Abstract 
The century-old relationship between centrosomes and cancer has remained a still unresolved 
question. Here we describe somatic mutations in CROCC gene, the major structural component of 
centrosome cohesion apparatus by sequencing  the whole exome from two patients with a rare and 
lethal tumor referred to as rhabdoid colorectal cancer.  We found that impaired CROCC activity at 
the “1p36.13” locus either caused by de novo somatic mutations or by copy number loss, results in 
aberrant centrosome phenotypes and unique catastrophic mitotic forms not recurrent in extrarenal 
rhabdoid or classical colorectal cancers. Our results demonstrate that reduced CROCC dosage, 
disrupts bipolar mitotic spindle architecture causing tetraploid DNA segregation errors and 
rhabdoid-like phenotype in vitro. In contrast, its restoration  in an metastatic model harboring 
1p36.13 deletion, arrests growth, corrects tetraploidy and centrosome segregation errors functioning 
as a biological barrier against replication stress and tetraploidy, two hallmarks of chromosomal 
instability.  Our work reveals  that impairing CROCC activity underlie rhabdoid tumors providing a 
link between centrosome genetic defects and human cancer, which may inform new therapeutic 
approaches to limit lethal phenotypes. 
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2. Introduction 
 
2.1 Centrosome 
 
 
2.1.1 Composition: centrioles and PMC 
 
Centrioles constitute the core of the centrosome. Centrioles are cylindrical structures that are ~450 
nm in height and ~250 nm in diameter, and characterized by a radial arrangement of nine peripheral 
microtubule triplets, as well as proximaldistal polarity along the cylinder. Centrioles are critical for 
recruiting the surrounding pericentriolar material (PCM). Although the PCM appears largely 
amorphous when observed by electron microscopy, super-resolution light microscopy reveals 
concentric layers of organization around the centriole. During interphase, an inner layer of PCM 
proteins is present next to centriolar microtubules, and notably contains the γ-tubulin ring complex, 
which is fundamental for microtubule nucleation. PCM architecture changes towards mitosis, with 
an expansion of the inner layer and the addition of further components, together resulting in a 
mature centrosome with maximal microtubule organizing centre (MTOC) activity. Whereas 
centrioles are crucial for PCM recruitment, the PCM reciprocally contributes to centriole 
biogenesis. 1  
 
 
 
2.1.2  Function 
 
In most animal cells, centrosomes are a major source of spindle microtubules, and they are 
absolutely essential for cell division in several early embryonic systems.  
It is clear, however, that centrosomes are not absolutely essential for division in many cell types. 
When centrosomes are absent, either naturally (as in higher plants or in the female germ cells of 
many animal species) or due to experimental manipulation, bipolar spindles can form in the vicinity 
of chromosomes through a centrosome-independent pathway that involves the small GTPase Ran 
and the action of microtubule motors and microtubule-bundling proteins. This pathway also 
presumably explains the surprising finding that Drosophila mutants lacking the centriole duplication 
protein DSas-4 appear to proceed normally through most of development, provided that a 
maternally supplied pool of DSas-4 is initially present to allow centrosome formation during the 
earliest stages of embryogenesis. In these mutants, centrioles and centrosomes are undetectable in 
adult cells, yet adults appear morphologically normal and eclose with nearnormal timing at near-
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normal Mendelian ratios. This is in stark contrast to the rare larvae that develop to adulthood in 
many mutants that show dramatic defects in cell division. Thus, although spindle assembly is 
slowed in fly cells that lack centrosomes, flies appear to proceed through most of development 
relatively normally using only the centrosome-independent pathway of spindle assembly. Perhaps 
this reflects the fact that Drosophila cells have only four chromosomes to segregate, and organisms 
with larger numbers of chromosomes may depend on the greater efficiency of spindle assembly 
afforded by centrosomes—an intriguing notion that remains to be experimentally tested. 
Interestingly, Drosophila mutants that lack centrioles nevertheless die soon after they eclose. Rather 
than reflecting the absence of centrosomes, however, this death appears to result from the lack of 
cilia that are essential for the function of certain mechano- and chemosensory neurons. These 
observations support the view that centrioles may have originally acquired the ability to form 
centrosomes not to increase the efficiency of cell division but rather to ensure that the centrioles 
associate with the spindle poles and are thereby equally partitioned between the two daughter cells. 
Although many somatic cells can clearly divide without centrosomes, there is compelling evidence 
that centrosomes are required for the efficient division of cells that split asymmetrically to produce 
two daughter cells of different fates. Although centrosomes are not essential for cell division in all 
cell types, there is evidence that they contribute to efficient cell-cycle progression at both the G1/S 
and the G2/M transitions. In response to experimentally induced perturbation of centrosomes, some 
vertebrate cells undergo a G1 arrest, prompting speculation that a specific checkpoint might monitor 
the functional integrity of the centrosome. 
During S phase, a subpopulation of cyclin E associates with centrosomes and possibly contributes 
to the regulation of S phase entry, and several cell-cycle regulatory proteins are concentrated at 
centrosomes and spindle poles during mitosis. These observations have led to the proposal that 
centrosomes might function as “scaffolds” to promote interactions between various regulatory 
components during the cell cycle. At the G2/M transition, the key mitotic kinases Cdk1/Cyclin B, 
Aurora-A, and Polo family members all accumulate at centrosomes, and the mitotic activation of 
Cdk1 is first detected at centrosomes. There are also several reports indicating that components of 
the DNA-damage checkpoint are concentrated at centrosomes. 2 
 
 
 
2.1.3  Duplication 
 
Proteins that have critical roles in centrosome duplication cycle have been discovered more 
recently, setting the stage for a molecular interrogation of the relationship between centrosomes 
and cancer. Most proliferating cells are born with two centrioles that are loosely connected via a 
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proteinaceous linker. These two centrioles are usually close to one another in the G1 phase of the 
cell cycle, effectively constituting a single MTOC. Typically around the G1/S transition, one 
procentriole begins to assemble orthogonal to the proximal end of the mother centriole and the 
daughter centriole. The two procentrioles then elongate during the remainder of the cell cycle while 
remaining engaged with their neighbouring centriole. The spatial relationship of the two 
centrosomes changes at the G2/M transition. First, the proteinaceous linker connecting them is 
removed following activation of the serine/threonine kinase NEK2, in a step referred to as 
centrosome disjunction. Second, the two centrosomes separate along the nuclear envelope before 
nuclear envelope breakdown, in a step dubbed centrosome separation. This process is thought to be 
driven principally by kinesin 5, a tetrameric plus-end-directed motor that pushes apart overlapping 
microtubules located between the centrosomes. Thereafter, the two separated MTOCs direct the 
assembly of the bipolar spindle, which ensures faithful segregation of the genetic material to 
daughter cells. During mitosis, the centriole and procentriole disengage from one another within 
each centrosome, so that each daughter cell inherits two centriolar cylinders, thus completing the 
duplication cycle. 1 
 
 
 
2.1.4  Centrosome and cancer 
 
Centrosome abnormalities, usually increased numbers, are common in human tumours and 
experimentally induced tetraploid cells  from extra centrosomes, can be critical for aneuploidy and 
metastatic potential, however, the key factor underlying centrosome anomalies in tumorigenesis 
remains unclear. 3 
A signature feature of cancer is uncontrolled progression through the cell cycle. Therefore, 
understanding how the centrosome duplication cycle is coupled to the cell cycle is crucial for 
evaluating how centrosomes may participate to control proliferation.  Core components of the cell 
cycle machinery regulate the centrosome duplication cycle, with two particularly important 
coupling points at the G1/S and G2/M transitions.  
Furthermore it has been ever clear that cancer cells frequently exhibit aberrant mitotic figures, an 
observation that fuelled the postulate that extra centrosomes contribute to genome instability. 
Experiments with antibodies directed against centriolar components established the presence of 
centrosome aberrations, including excess centrioles, longer centrioles, excess PCM, as well as 
changes in centrosome shape and size, occurring both in cells from solid tumours and in 
haematological malignancies. Such aberrant figures can be present in pre-invasive lesions, and their 
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frequency often correlates with tumour progression raising the possibility that centrosome 
aberrations promote cancer progression. 
The extent of extra centrosomes correlates with that of Chromosomal instability (CIN) in many 
human cancers. CIN that refers to the propensity of cell populations to change their chromosome 
complement over time, is a hallmark of cancer 
Yet, a causal relationship between centrosome abnormalities and cancer has been difficult to 
establish. The deregulation of several oncogenes and tumor suppressor genes is well known to 
affect the number of centrosomes. 
In this scenario, the rare and extremely aggressive entity referred to as rhabdoid colorectal cancer 
(RC), with a median survival of 6 months, remains uncharacterized. 1-2 
 
2.2 Rhabdoid colorectal cancer 
2.2.1 Generality 
 
Rhabdoid cancer is an extremely rare and highly aggressive tumor type with no proven effective 
treatment.4 
The first reported case of rhabdoid tumor was a malignant pediatric renal neoplasia, a variant of 
Wilms tumor, with histologic features of rhabdomyoid-like appearance5. Malignant rhabdoid kidney 
tumors are considered a distinct clinicopathologic entity based on morphologic findings and a high 
metastatic potential. Tumors with similar features have been reported in several other organs such 
as esophagus, stomach, small intestine, heart, skin, and colon rectum. In this scenario, the rare and 
extremely aggressive entity referred to as rhabdoid colorectal cancer (RC), with a median survival 
of 6 months, remains uncharacterized. To date, only 23 cases of colorectal adenocarcinoma with a 
rhabdoid dedifferentiated phenotype have been reported, indicating that it is extremely rare4,6-23 
(TABLE 1). RCs occur in adults (range, 31-87 years) suggesting a tendency to develop in older 
patients and are morphologically indistinguishable from extrarenal rhabdoid tumors (ERTs) 
typically affecting infants and young adults. A common features of extrarenal rhabdoid tumors is 
the presence of metastasis at diagnosis and patient poor prognosis6. Clinically, the majority of 
colorectal rhabdoid cancers arise in cecum and transverse colon, and can display either a “pure” 
rhabdoid morphology when the rhabdoid features are the only identifiable phenotype  or more often 
“composite” when the rhabdoid phenotype is mixed with another type of identifiable neoplasm. 
Histologically, the rhabdoid phenotype is characterized by the presence of pleomorphic cells with 
large, eccentric nuclei, prominent nucleoli, abundant and eosinophilic cytoplasm, paranuclear 
inclusions of intermediate filaments, and abundant mitotic figures. Cytokeratin and vimentin are 
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frequently found on immunochemistry21. It is equally distributed between both sexes with 13 males 
and 10 females. Almost all patients presented with abdominal symptoms including abdominal pain, 
abdominal mass, and gastrointestinal bleed. This is quite an unusual presentation of colon cancer 
that tends to have more occult presentation and could be a reflection of the aggressive nature of this 
type of tumor. 
 
 
 
2.2.2   Molecular mechanisms 
Previous efforts to gain insight into the molecular mechanisms underlying rhabdoid phenotype are 
limited to pediatric malignancies, which are characterized by low mutation load and a inactivating 
mutation and/or deletion of the chromatin remodelling gene SMARCB1 (INI1) residing at 
chromosome 22q11.2. 
Infact Rhabdoid tumors are typically diagnosed in infants and children, but they can occur at any 
age. Rhabdoid tumors have been described in virtually every anatomic site, including the brain, soft 
tissue, lungs, ovaries, and liver, but they most frequently originate in the kidneys and brain. 
Rhabdoid tumors originating in any location receive the generic name of malignant rhabdoid tumors 
(MRT). However, when MRT arise in the kidney they are specifically called rhabdoid tumors of the 
kidney (RTK), and when they arise in the brain, they are called atypical teratoid/rhabdoid tumors 
(AT/RT). The name AT/RT was conceived by Rorke and colleagues when rhabdoid tumors of the 
central nervous system were defined as a new entity. It reflects the ‘‘unusual combination of mixed 
cellular elements similar to but not typical of teratomas’’ observed in that group of tumors. 
Currently, rhabdoid tumors originating at any anatomic location are recognized as the same tumor 
type, with similar morphology, biology, and clinical behavior. The cell origin of MRT remains 
unknown. In a report based on a microarray gene expression study, Sredeni and collegues suggested 
that rhabdoid tumors may arise through a developmental arrest of neural crest stem cells24 
Treating AT/RT requires surgically resecting as much of the tumor as possible while preserving 
neurologic function, followed by an intensive multimodal regimen. Chemotherapy may include 
vincristine, cisplatin, cyclophosphamide, etoposide, actinomycin D, and temozolomide. The 
addition of intrathecal chemotherapy and radiation therapy depends on the child’s age and the 
extent of the disease . This regimen has significantly improved patients’ survival rates. Regrettably, 
despite the progress, the treatments’ toxic side effects are substantial, and most patients still rapidly 
succumb to their diseases. 25 
Regardless of their site of origin, the vast majority of MRT demonstrate abnormalities in 
chromosome 22. 26 
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SMARCB1, stands for SWI/SNF-related, matrix-associated, actin-dependent regulator of 
chromatin, subfamily b, member 1. The SWI/SNF chromatin-remodeling complex consists of 12–
15 subunits and uses energy obtained from adenosine triphosphate (ATP) hydrolysis to remodel 
nucleosomes and modulate gene transcription. Mutations in genes encoding these subunits, 
structural abnormalities, or epigenetic modifications that lead to reduced or aberrant expression of 
members of the SWI/SNF complex have been reported in 20% of human cancers. The member of 
this complex encoded by the SMARCB1 gene is recruited to various chromatin regions, including 
gene promoters, that regulate cell cycle, growth, and differentiation The SMARCB1 abnormalities 
in rhabdoid tumors are characterized as somatically acquired biallelic inactivating truncating 
mutations within tumors with or without a predisposing germline mutation. This characteristic 
implicates SMARCB1 as a tumor suppressor gene, as defined by Knudson in the ‘‘two-hit 
model’’.25 
Recently, a 2nd core element of the SWI/SNF chromatin-remodeling complex, the SMARCA4 
gene, also known as BRG1 and located at 19p13.2, was found to be inactivated in rare cases of 
rhabdoid tumors that retained SMARCB1 expression, as detected by immunohistochemistry. 27 
Malignant rhabdoid tumors are polyphenotypic tumors that express markers of divergent 
differentiation. Rhabdoid tumors have a classic immune profile that shows diffuse expression of 
smooth muscle actin, epithelial membrane antigen, and vimentin. These markers are associated with 
variable expression of neuron-specific enolase, Leu7, and S100; absence of expression of muscle 
markers such as desmin and myogenin; and loss of expression of SMARCB1. Documenting loss of 
SMARCB1 protein expression is particularly useful to characterize the tumor and should be 
included in the final diagnosis. 25 
It has been estimated that up to one third of patients with rhabdoid tumors harbor SMARCB1 
germline inactivating mutations. Although most of these mutations seem to occur de novo, familial 
cases have been reported in which an inherited constitutional SMARCB1 mutation of 1 allele 
predisposes a patient to developing a rhabdoid tumor. This condition is known as rhabdoid tumor 
predisposition syndrome (RTPS). 28 
 
By contrast, information on molecular anomalies of RCs is limited to rare cases previously 
described by (Pancione and Remo) wich showed microsatellite instability (MSI), BRAFV600E 
mutation and CpG island methylator phenotype (CIMP). They analyzed promoter DNA methylation 
of subset of genes highly specific to characterize the CIMP status (NEUROG1, IGF2, RUNX3, 
SOCS1, including MLH1). From these analyses, they found MLH1 promoter hypermethylation, 
which—associated with negative MLH1 immunostaining—confirms MSI-H. 
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In addition, aberrant DNA promoter methylation was identified in multiple loci: NEUROG1, IGF2, 
RUNX3, and SOCS1, suggesting the presence of a CIMP-positive tumor (data not shown). 
Altogether, these data implyed that rhabdoid features were closely correlated with presence of MSI, 
CIMP+ tumor, and BRAFV600E mutation. No driver mutations-associated phenotypes have been 
reported in any of these cases. 
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3. Material and methods 
 
 
   3.1 Research Subjects and Rhabdoid Tumors 
Seven cases of primary rhabdoid tumour arising in colorectum (RC) and matched normal samples 
were recruited from different medical institutions: a) Konkuk University School of Medicine, Seoul 
University, Seoul, Korea; b) Hospital Santariskiu Clinics, National Affiliate of Vilnius University 
Hospital Santariskiu Clinics, Vilnius, Lithuania. c) Mater Salutis” Hospital, Legnago, Verona, Italy. 
The discovery samples included paraffin embedded specimens of rhabdoid tumour component and 
matched non-neoplastic mucosa from two patients with primary rhabdoid tumour arising in 
colorectum (RC), who were recruited at the “Mater Salutis” Hospital, Legnago, Verona and “G. 
Rummo” Hospital, and Benevento, Italy.6,17,19, 20, 24 To be included in the study a centralized 
revision of all cases was performed, the hematoxylin-eosin–stained (H&E) glass slides were 
independently reviewed by pathologists to confirm the diagnosis and to look for the presence of 
strict rhabdoid morphology as previous described. Five out of the seven cases of the cohort have 
been reported previously. 6,17,19,20,29 Two cases have not been reported before (VI, VII). 
Clinicopathologic features of RCs are summarized in (Table 1). Additional seven cases of 
“extrarenal rhabdoid tumors” affecting central nervous system of patients between 2 months  and 19 
years of age, diagnosed between 2007-2015, were recruited from the “Azienda Ospedaliera 
Universitaria Integrata”, Verona, Italy. The pediatric rhabdoid tumors were indicated as Rhabdoid 
of infant (RI) through the study. The main clinicopathologic features of the 7 pediatric rhabdoid 
tumors are summarized in (Table 2). For all cases of rhabdoid tumors, matched normal-tumor pairs 
consisting of formalin fixed paraffin-embedded (FFPE) tissue blocks, at the time of the initial 
surgery, were collected. 
 
 
 
 
 
 
 
13 
 
Table 1. Rhabdoid colorectal cancers: clinicopathological, immunohistochemical and molecular 
characteristics of the 7 cases  
Clinicopathological features 
Case 
 
Age 
(years) 
Sex 
 
Location 
  
Size 
(cm) 
pT 
 
Metastasis 
 
Follow 
up 
 
Status 
 
Reference 
 
RC 1* 73 Female Cecum 10x8 4 Lymph nodes 
6 
months 
Dead # 
RC 2* 71 Male Cecum 10x10 4 Lymph nodes 
8 
months 
Dead # 
RC 3 62 Male Sigma 4.5x4 3 Lymph nodes 
36 
months 
 Alive # 
RC 4 83 Female Rectum 6.5x4.3 4 Liver, Lung 1 month Dead # 
RC 5 49 Male Sigma 7x7 4 Lymph nodes 
7 
months 
 Dead # 
RC 6 63 Male Left colon 6 x6 3 Lymph nodes 1 month  Dead none 
RC 7 71 Female Cecum 8x11 4 Lymph nodes 
8 
months 
 Dead none  
              
Immunohistochemical analysis 
Case CK20 CDX2 Vimentin Mhl1 Pms2 Msh2 Mlh6 p53 SmarcB1/ Ini1 
RC 1* - - + - - + + ++ neg. 
RC 2* - - + - - + + ++ ++ 
RC 3 - + + + + + + - ++ 
RC 4 - - + + + + + - ++ 
RC 5 - - + + + + + None ++ 
RC 6 - - + + + + + None neg. 
RC 7 - - + - - + + ++ ++ 
 
 
 
Molecular analysis 
 
 
 
 
 
 
 
  
 
Notes and abbreviations: *, cases subjected to exome sequencing;  pT, pathological stage, where T3 is infiltration of 
the intestinal wall, and T4 is extension to perivisceral fat; +, positive immunostaining; -, negative immunostaining. 
Cases MSI CIMP BRAF  KRAS APC TP53 
RC 1* MSI-H pos (6/6) MUT WT WT WT 
RC 2* MSI-H pos (5/6) MUT WT WT WT 
RC 3 MSS pos (3/6) WT WT MUT WT 
RC 4 MSS Neg(1/6) MUT WT WT MUT 
RC 5 MSS pos (5/6) MUT WT WT WT 
RC 6 MSS pos (4/6) MUT MUT MUT MUT 
RC 7 MSI-H Pos (5/6) MUT WT WT MUT 
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Abbreviation: Tumors with at least three methylated loci of the following CIMP loci (RUNX3, IGF2, SOCS1, 
NEUROG1, CDKN2A  and hMLH1) were classified as CpG island methylator phenotype (CIMP)-positive and the 
remaining cases as CIMP-negative. 
 
 
Table 2. Infants/young adults rhabdoid cancers of the central nervous system: clinicopathological and 
immunohistochemical features of the 7 cases.  
Case 
 
Age 
 (years) 
Sex 
 
Location 
 
INI1  
(IHC) 
CROCC 
(IHC) 
Follow up 
(months)  
Status 
 
RI 1 2 F CNS - - n.a. n.a. 
RI 2 2 months M CNS - Single, large centriol 3 Dead 
RI 3 4 M CNS + Single, large centriol 33 Alive 
RI 4 5 M CNS - Single, large centriol 21 Dead 
RI 5 10 F CNS + Single, large centriol 92 Alive 
RI 6 6 M CNS - Single, large centriol n.a. n.a. 
RI 7 19 F CNS - Single, large centriol 46 Alive 
 
CNS, central nervous system; AT/RT, Atypical teratoid rhabdoid tumor 
n.a., Not Available 
 
 
 
3.2 FFPE DNA extraction.  
The tumoral area with rhabdoid morphology was identified by  H&E staining, whereas, manual 
macrodissection was performed on the FFPE blocks using a scalpel. Briefly, samples were then 
incubated at 90 °C to remove DNA crosslinks, and extraction was performed using Qiagen's 
QIAamp DNA FFPE Tissue Kit according manufacturer’s instructions. DNA concentration was 
determined with both spectrophotometric Nanodrop 1000 (Thermo fisher, Wilmington, DE, USA) 
and fluorometric  Picogreen dsDNA kit  (Invitrogen, Inchinnan, UK) methods. On average, the 
concentration measured with picogreen was half the concentration estimated with Nanodrop.   
 
3.3 Whole-Exome Sequencing 
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Isolated genomic DNA “1.3 µg”  was sheared to 100-450 bp on a Covaris S220 instrument 
(Covaris, Woburn, Ma, USA). Distribution of fragments size was verified with an Agilent 2100 
Bioanalyzer using a DNA 1000 assay (Agilent, Santa Clara, CA, USA). Sheared DNA was 
subjected to Illumina paired-end DNA library preparation using the TruSeq DNA Sample 
preparation kit (Illumina, San Diego, CA, USA) and  enrichment for whole exome was carried out 
according to the TruSeq Exome Enrichment Guide  (Illumina, San Diego, CA, USA). Briefly, 
fragmented DNA was end-repaired and adenylated before the ligation of an 
indexing  adapter.  After the subsequent PCR amplification, the quality of the library was evaluated 
with an Agilent High Sensitivity DNA assay  (Agilent, Santa Clara, CA, USA) and then 
quantified  using the Quant-iT PicoGreen dsDNA Assay Kit (Thermo fisher, Wilmington, DE, 
USA)  on a NanoDrop 3300 fluorospectrometer (Thermo Scientific, Wilmington, DE, USA). 
Exome capture was performed using 500 ng of library as input material. Next, half biotinylated 
bait-based hybridizations were performed, each followed by Streptavidin Magnetic Beads binding, 
a washing step and an elution step. Libraries were amplified with 10 PCR amplification cycles. The 
quality of the whole exome library was checked with an Agilent High Sensitivity DNA assay and 
quantified by qPCR on a Stratagene MX3000P (Agilent, Santa Clara, CA, USA) using Kapa 
Library Quant kit (Kapa Biosystems, Boston, MA, USA). Whole exome library was sequenced with 
an Illumina HiSeq 1000 sequencer (Illumina, San Diego, CA, USA) and 100-bp x 2 paired-end 
sequences were generated. The sequences were pre-processed by removing reads with a percentage 
of undetermined bases (N) higher than 10% of the length of the read and more than 50 bases with a 
quality lower or equal to 7. Adapters were clipped using Scythe v0.980 
(https://github.com/vsbuffalo/scythe) and 3′ ends with a quality score lower than 20 over a window 
of 10 bases were trimmed using Sickle v0.940 (https://github.com/vsbuffalo/sickle), eventually 
entirely removing the fragment if the final length of one of the reads was lower than 50 bp. Filtered 
reads were aligned against the reference hg19 genome using BWA 0.6.2 using default 
parameters.30,31  Duplicates were marked with Picard tools and reads were realigned in 
correspondence of indels and recalibrated using GATK 2.6-5.32,33 Variants were called with Mutect 
v1.1.4 using default parameters  and with GATK 2.6-5 UnifiedGenotyper module with “-glm 
BOTH” parameter.34 Functional annotation of mutations was performed with Annovar and cancer 
driver analysis with CRAVAT.31   
3.4 Tumour purity, copy number and structural variations analysis 
The purity of the tumor samples was estimated using SNP array data with the Allele-specific copy 
number analysis of tumors (ASCAT) algorithm as reported.35 SNP arrays were scanned and data 
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was processed using the Genotyping module (v1.8.4) in Genome studio v2010.3 (Illumina, San 
Diego, CA, USA) to calculate B-allele frequencies (BAF) and logR values. GenoCN43 and GAP17 
were used to call somatic regions of copy number change – gain, loss or copy neutral LOH. 
Recurrent regions of copy number change were determined and genes within these regions were 
extracted using ENSEMBL v70 annotations. Depending on the read pair types supporting an 
aberration or the associated of copy number events each structural variant was classified as: 
deletion, duplication, tandem duplication, foldback inversion, amplified inversion, inversion, 
intrachromosomal or translocation. Essentially, the type of rearrangement is initially inferred from 
the orientation information of discordant read pairs, soft clipping clusters and assembled contigs 
which span the breakpoints. Structural variants with breakpoints that flanked a copy number 
segment of loss were annotated as deletions. Duplications and inversions associated with increases 
in copy number enabled the characterization of tandem duplications and amplified or foldback 
inversions. Events within the same chromosome which linked the ends of copy number segments of 
similar copy number levels were identified. Events were then annotated if they were within 100 kb 
of a centromere or telomere and genes which were affected by breakpoints were annotated using 
ENSEMBL v70. Somatic copy number variation, structural variants and copy number data were 
visualized using circus.36 
 
 
 
3.5 Splice-site prediction tool and driver genes analysis 
To predict the splicing mutations that affected donor and acceptor splice sites and to evaluate the 
efficiencies of physiological splicing sites in mutant genomic sequence Mutation Taster tool was 
used. To further evaluate  the disease-causing potential on both exonic and nonexonic variants, we 
also used SpliceFinder which is a method for rapid functional prediction of splicing variants starting 
from a large set of somatic mutations obtained by whole-exome sequencing analysis.13  The 
SpliceFinder methodology is a bioinformatics integrated procedure based on two public functional 
annotation tools for HTS analysis, ANNOVAR and MutationTaster  and two canonical splice-site 
prediction software programs for single splicing analysis, SSPNN 
(http://www.fruitfly.org/seq_tools/splice.html and NetGene2 (http://www.cbs. 
dtu.dk/services/NetGene2/.37-39 The candidate variant was accepted as putative splicing mutation 
and sequenced by Sanger method whereby the prediction was confirmed using both programs. To 
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identify putative  driver mutations that are required for the cancer phenotype, the computational 
tool, DrGaP (driver genes and pathways) was applied to the common mutated genes from cancer 
genome-sequencing. This tool incorporates statistical approaches and several auxiliary 
bioinformatics tools for better driver gene identification.40  
 
3.6 Sanger sequencing validation  
We used polymerase chain reaction (PCR) amplification and direct DNA sequencing to validate 
candidate variants in CROCC gene identified by WES (Table 3).  Because of the sensitivity of 
Sanger, sequence variants that were reported in less than 20% of the reads could not be included in 
this validation phase. The purified products were subsequently sequenced with the use of the 
BigDye Terminator, version 3.1, Cycle Sequencing Kit (Life technology, Carlsbad, CA, USA). 
Data were analyzed with BioEdit Sequence Alignment Editor 7.0.5.3. 
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Table 3. reverse transcription and sequencing PCR primers 
 
 
 
 
CROCC primers 
Gene Sense Antisense  
RTPCR-
CROCC-II  
5’ACATGACCGCCAAGTACTCC3’ 
 
5’CCTCCCGTAGCTGTTGTAGC3’ 
 
     
RTPCR-
CROCC-I 
5’CTGAGGGACACAGAGCACAG3’ 
 
5’TCCTCACTCAGAGCCTGGTT3’ 
 
 
Seq-CROCC   5’AAATTGGAGGAGACGGCTTT3’                      5’CAGCTTCTGCTCCTTGTCCT3’  
 
RAC1 5′-GCCAATGTTATGGTAGAT-3′ 5′-GACTCACAAGGGAAAAGC-3′  
CDX2  5’ AAAGTGAGCTGGCTGCCACACTTG 3’ 5’ TCCATCAGTAGATGCTGTTCGTGG 3’  
KRT20 5’CTGAATAAGGTCTTTGATGACC 3’ 5’ATGCTTGTGTAGGCCATCGA 3’  
CDH1 5’GAACGCATTGCCACATACAC 3’ 5’ATTCGGGCTTGTTGTCATTC 3’  
LAMA5 5’AAGATGGCGAAGCGGCTCT  3’ 5’ TTGAAGTAGGGCGGGTGCAG 3’  
KRT18 
 
5’ TTTCCCAGATCATGGAGGAG 3’ 
 
 
5’AGCCCATGAGGTTTTTCTGA3’ 
 
 
VIM  5’TGACAATGCGTCTCTGGCAC 3’ 5’CCTGGATTTCCTCTTCGTGG 3’  
18S  5’GGGAGCCTGAGAAACGGC 3’ 5’GGGTCGGGAGTGGGTAATTT 3’  
ACTB GCTCACCATGGATGATGATATCGC ATAGGAATCCTTCTGACCCATGCC  
ACTG2 5’-CCGCCCTAGACATCAGGGT-3’ 5’-TCTTCTGGTGCTACTCGAAGC-3’  
SMARCB1 5’TCCGTATGTTCCGAGGTTC3’ 5’CTTCCACTTCCGAGGCTTT3’  
CEP152 5'-CCATGTCAGCTTGTTCTTCC-3' 5'-CACCTTTCTCTTCTCCTGCT-3'  
CEP192 5’CCCAACGACCTAATGATGTTCA3’ 5’GCTCCCAAGTCGCTTGTAGATT3’  
CDKN2B 5’TACAGGAGTCTCCGTTGGC3’ 5’GTGAGAGTGGCAGGGTCTG3’  
CDKN2A 5’CCACCCTGGCTCTGACCAT3’ 5’GCCACTCGGGCGCTG3’  
CDH2 5'-GGCATAGTCTATGGAGAAGT-3' 
5'-GCTGTTGTCAGAAGTCTCTC-3' 
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3.7 Public Database as a Reference  and  Sequencing data  
We used gene expression data estimated from whole exome sequencing (WES), whole 
transcriptome sequencing (WTS), to select possible functional genetic changes in our study. 
Because RC is a rare disease and obtaining control samples is not easy, we used a public database 
as a reference. Preprocessed level 2 somatic mutation data, Affymetrix SNP 6.0, were downloaded 
(n=631 CRC samples) by using the most recent update of the raw sequencing TCGA data set.41 The 
logR ratios and allelic differences and copy number were estimated by the Affymetrix Genotyping 
Console.41,42  Ploidy was estimated by calculating the weighted median copy number across all 
copy number segments, with weights equal to the segment length. Copy number segments of loss 
and gain were defined relative to the ploidy status of each sample by subtracting the ploidy estimate 
from the estimated copy number of the segment for which SNP 6.0 copy number data was also 
available. For RNA-seq data, enrichment analysis was performed using the R package GOseq to 
correct for bias due to transcript length, considering only categories with at least ten annotated 
genes. We annotated all samples contained within it either as colorectal cancer (n = 382) or normal 
colon mucosa (n = 21) from TCGA data set, and we compared the RPKM value of specific genetic 
changes found in our analysis with normal colon expression values.41  For copy number alteration 
(CNA) analysis of WES data, we used the Copy Number Analysis for Targeted Resequencing 
(CONTRA) tool and summarized the exon-level log2 fold changes of read depth between the 
normal and tumor samples into gene-level log2 fold changes.43  The bioinformatics search of 
CROCC gene mutation across cancer types  started from a large collection of publicly available 
human gene-expression array experiments downloaded from the National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo) 
and TCGA . For recurrence of  CROCC somatic mutations,  “mutation data were filtered for exons 
and at splice sites (±3 bp)”, copy number changes, mRNA transcript levels across different tumour 
types and cancer cell lines we used datasets from TCGA (https://tcga-data.nci.nih.gov) and 
cBioPortal for Cancer Genomics (http://www.cbioportal.org). The colorectal, rhabdoid or 
neuroblastoma  cancer cell lines studied were obtained from  cBioPortal for Cancer Genomics.  
Colorectal cancer cells were classified as CIN+ or (aneuploid) or CIN- (non-aneuploid) using 
weighted GII .0.2. For the 60 colorectal cancer  cell lines, the total number of putative somatic 
mutations ranged from 0 to 1308. Cell lines with a mutation prevalence of >25 per 106 bases were 
designated as hypermutated, as reported.44,45 These latter,  showed  a modal chromosome copy 
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number of 2n, by contrast, nonhypermutated cells tended to exhibit unstable profiles with modal 
chromosome copy numbers ranging from 2n to 4n in cell lines. 44,45  To define the gene-array 
expression thresholds used to separate cancer cell lines  harboring 1p36.13 deletion,  from those 
retaining 1p36.13 locus supervised clustering analysis  with FDR<0.01  based on spearman and 
ward linkage was used. The P values were adjusted for multiple testing with the Benjamini and 
Hochberg method.46 
3.8 Gene ontology enrichment analysis 
The enrichment analysis was performed with the TopGO package using the classic algorithm and 
Fisher’s test with the same cutoffs described above.44-46 Genes tested for differential expression 
were used as the background. To create enrichment treemaps, parent categories that had enriched 
children were first removed, and maps were then created with the Treemap package, color coding 
categories according to the combination of non-overlapping parent categories accounting for the 
largest proportion of plotted categories. All reported P values were calculated using the Benjamini-
Hochberg method.   To understand causal connections between diseases, genes and networks of 
upstream or downstream regulators the samples were subjected to Ingenuity Pathways Analysis 
(IPA) (Ingenuity Systems) which was used as a starting point for building biological networks. 
 
 
 
3.9 CROCC target sequencing  
A multigene panel was developed using AmpliSeq designer software v2.1 to investigate the coding 
sequences of CROCC (NM_014675.3) genes. Details on target regions of the panel are reported in 
(Table 4). Suitability of extracted DNA from FFPE sections was evaluated and quantified as 
described above. To further verify DNA integrity a multiplex a multiplex PCR was performed  
according to previous studies. 47-49 Briefly, twenty nanograms of DNA were used for each multiplex 
PCR amplification. Then, PCR amplified fragments to build an adequate library for deep 
sequencing were successfully obtained. The mean read length was 112 base pairs and a mean 
coverage of 6290x was achieved, with 94.1% target bases covered more than 100x. A minimum  
coverage of 20x was obtained in all cases. The quality of the obtained libraries was evaluated by the 
Agilent 2100 Bioanalyzer on-chip electrophoresis (Agilent, Santa Clara CA, USA). Emulsion PCR 
to construct the libraries of clonal sequences was performed with the Ion OneTouch™ OT2 System 
(Life technology, Carlsbad, CA, USA). Sequencing was run on the Ion Personal Genome Machine 
(Life technology, Carlsbad, CA, USA) loaded with Ion 318 Chip v2 (. Data analysis, including 
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alignment to the hg19 human reference genome and variant calling, was done using the Torrent 
Suite Software v.5.0 (Thermo fisher scientific, Whaltam, MA, USA). Filtered variants were 
annotated using a custom pipeline based on vcflib (https://github.com/ekg/vcflib), SnpSift, the 
Variant Effect Predictor (VEP), software and NCBI RefSeq database. Additionally, alignments 
were visually verified with the Integrative Genomics Viewer (IGV) v2.3 to further confirm the 
presence of mutations identified by targeted sequencing.49-51  
 
Table 4. CROCC custom panel used for the next-generation target sequencing. 
Gene Chr Start End  Gene Chr Start End  Gene Chr Start End 
CROCC chr1 17248461 17248565  CROCC chr1 17271988 17272118  CROCC chr1 17287230 17287347 
CROCC chr1 17248554 17248670  CROCC chr1 17272134 17272224  CROCC chr1 17287637 17287723 
CROCC chr1 17249085 17249217  CROCC chr1 17272675 17272775  CROCC chr1 17292117 17292245 
CROCC chr1 17249160 17249244  CROCC chr1 17272738 17272848  CROCC chr1 17292222 17292343 
CROCC chr1 17250720 17250829  CROCC chr1 17273186 17273323  CROCC chr1 17292322 17292437 
CROCC chr1 17250799 17250931  CROCC chr1 17274660 17274791  CROCC chr1 17292383 17292508 
CROCC chr1 17250873 17250992  CROCC chr1 17274780 17274917  CROCC chr1 17292504 17292599 
CROCC chr1 17250976 17251089  CROCC chr1 17274933 17275069  CROCC chr1 17292628 17292729 
CROCC chr1 17256284 17256403  CROCC chr1 17275203 17275319  CROCC chr1 17292742 17292867 
CROCC chr1 17256414 17256546  CROCC chr1 17275297 17275411  CROCC chr1 17292883 17293016 
CROCC chr1 17256533 17256633  CROCC chr1 17275424 17275510  CROCC chr1 17293026 17293116 
CROCC chr1 17256637 17256752  CROCC chr1 17277375 17277491  CROCC chr1 17294680 17294776 
CROCC chr1 17256905 17257024  CROCC chr1 17277480 17277608  CROCC chr1 17294770 17294880 
CROCC chr1 17257013 17257116  CROCC chr1 17277597 17277687  CROCC chr1 17294899 17294999 
CROCC chr1 17257674 17257770  CROCC chr1 17279663 17279769  CROCC chr1 17295543 17295679 
CROCC chr1 17257742 17257870  CROCC chr1 17279774 17279898  CROCC chr1 17295668 17295803 
CROCC chr1 17257818 17257943  CROCC chr1 17279902 17280005  CROCC chr1 17295792 17295910 
CROCC chr1 17263077 17263164  CROCC chr1 17279976 17280095  CROCC chr1 17296213 17296351 
CROCC chr1 17263141 17263233  CROCC chr1 17280645 17280757  CROCC chr1 17296329 17296458 
CROCC chr1 17263263 17263365  CROCC chr1 17280746 17280866  CROCC chr1 17296433 17296527 
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3.10 RAS and BRAFV600E  Mutation Analyses 
RAS and BRAFV600E mutations were investigated on DNA extracted from FFPE tumor tissues using 
real-time polymerase chain reaction (PCR) on RotorGene Q MDx instruments (Qiagen, Hilden, 
DE). Scorpions® and ARMS® technologies were employed  to detect KRAS mutations at the 
codons 12 and 13 (exon2) and BRAFV600E mutation at the codon 600 (V600E/Ec,D,K,R) against the 
background of wild type genomic DNA (Therascreen® RGQ PCR Kit) (Qiagen, Manchester UK). 
CROCC chr1 17263352 17263433  CROCC chr1 17280826 17280935  CROCC chr1 17296665 17296798 
CROCC chr1 17264084 17264185  CROCC chr1 17281146 17281235  CROCC chr1 17296794 17296903 
CROCC chr1 17264174 17264285  CROCC chr1 17281217 17281347  CROCC chr1 17296879 17296990 
CROCC chr1 17264739 17264868  CROCC chr1 17281374 17281456  CROCC chr1 17296947 17297081 
CROCC chr1 17264859 17264949  CROCC chr1 17281702 17281837  CROCC chr1 17297117 17297245 
CROCC chr1 17264963 17265050  CROCC chr1 17281854 17281992  CROCC chr1 17297164 17297289 
CROCC chr1 17265348 17265463  CROCC chr1 17282004 17282124  CROCC chr1 17297842 17297965 
CROCC chr1 17265665 17265771  CROCC chr1 17282412 17282530  CROCC chr1 17297937 17298073 
CROCC chr1 17266338 17266447  CROCC chr1 17282518 17282647  CROCC chr1 17298176 17298280 
CROCC chr1 17266441 17266572  CROCC chr1 17282591 17282712  CROCC chr1 17298746 17298876 
CROCC chr1 17266584 17266695  CROCC chr1 17284990 17285092  CROCC chr1 17298849 17298930 
CROCC chr1 17270505 17270588  CROCC chr1 17285081 17285215  CROCC chr1 17298955 17299075 
CROCC chr1 17270780 17270893  CROCC chr1 17285248 17285359      
CROCC chr1 17271855 17271963  CROCC chr1 17287132 17287241      
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The therascreen® NRAS Pyro® (Qiagen, Manchester UK) was used to determine additional 
mutations at the codons 61 (exon3) of the NRAS gene.  While the RAS Extension Pyro® kit was 
used to detect mutations at the codons 59,61 (only KRAS) (exon3) and 117, 146 (Exon4) of the 
KRAS and NRAS genes, respectively according manifactures’ istructions (Qiagen Manchester UK). 
The DNA segment of interest were amplified by PCR and sequenced separately. The distinct 
patterns in the Pyrogram® trace were distinguishable from the background obtained from wild-type 
samples.  
 
3.11 Targeting sequencing Hotspot Panel. 
DNA was extracted from FFPE tumor samples using the GeneRead DNA FFPE Kit (Qiagen, 
Hilden, DE). DNA quality and quantity were assessed using the Qubit Fluorometer (Invitrogen, 
Inchinnan, UK) and the 2200 Tape Station instrument (Agilent, Santa Clara CA, USA). Good 
quality genomic DNA was subjected to library preparation prior to sequencing. NGS analyses were 
performed on the Ion Torrent Personal Genome Machine (PGM, Life Technologies, Grand Island, 
USA). Tumor samples were tested using a commercially available library kit, the Ion AmpliSeq 
Cancer Hotspot Panel v.2 (CHP2) which allows for simultaneous amplification of 207 amplicons in 
hotspot areas of 50 oncogenes and tumor suppressor genes. Each amplicon library was generated 
starting from 10 ng of gDNA, as indicated by the manufacturer and the multiplexed PCR to amplify 
targets was performed in 20 cycles. Samples were barcoded with Ion Xpress Barcode Adaptors Kit 
(Life technologies, Carlsbad, CA, USA to allow for discrimination between samples within a NGS 
run. DNA Library quantification was performed using the PCR quantification kit and the 
Quantstudio 12k flex real time PCR system (Life technologies, Carlsbad, CA, USA, diluted in 
nuclease-free water to obtain a final concentration of 100 pM. The library was mixed with Ion 
Sphere Particles (ISPs) and the subsequent emulsion PCR and enrichment were performed using the 
Ion PGMTM Template OT2 200 Template Kit (Life technologies, Carlsbad, CA, USA. The quality 
of the emulsion PCRs was measured using the Qubit IonSphere Quality control kit (Life 
technologies, Carlsbad, CA, USA (Life Technologies). IonSphere were sequenced on Ion 316 Chip 
using the Ion PGM™ Sequencing 200 Kit (Life Technologies). Only sample sequences with at least 
a quality score of AQ20 (1 misaligned base per 100 bases) were considered for further analyses. 
Data obtained was processed initially using the Ion Torrent platform-specific pipeline software 
Torrent Suite to generate sequence reads, trim adapter sequences, filter, and remove poor signal and 
low quality reads. Mutations were called by the Torrent Variant Caller plug-in v 4.4.3.3 (Life 
technologies, Carlsbad, CA, USA. Subsequently, data were uploaded from Torrent SuiteTM 
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Software to Ion Reporter Software v 4.6 and analyzed with “AmpliSeq CHPv2 single sample” 
workflow.  
3.12 Immunohistochemical staining and analysis.  
Immunohistochemical analysis for CROCC was performed on tumor and matched normal tissue 
sections. Four µm-thick sections were obtained from FFPE blocks. They were deparaffinised with 
BOND DEWAX Solution (Leica biosystems, Newcastle, UK) placed in graded alcohol solutions, 
washed, and pretreated with the Epitope Retrieval Solution 2 (EDTA buffer pH8.8) at 98 °C for 20 
minutes. After the washing steps, peroxidise blocking was carried out for 5 minutes using the Bond 
Polymer Refine Detection Kit DS9800 (Leica biosystems, Newcastle, UK). Then, the sections were 
incubated with with a rabbit primary anti-human CROCC polyclonal  antibody, clone NBP1-80820,  
rabbit IgG, dilution 1:200, (ABCAM, Cambridge, UK) for 15 and secondary antibody for 8 
minutes, respectively. Subsequently, they were incubated with polymer (8 min), revealed with 
DAB-chromogen (10 min), and stained with hematoxylin (10 min). Fallopian tube (FT) tissues were 
used to develop CROCC immunohistochemistry protocol as recommended by supplier (positive 
control). In normal cells CROCC staining consisted of one or up to two dot-like signals. 
Consistently, the expression pattern was stratified into three categories: a) Loss, less than 1 per cell 
b) normal,  1-2 signals per cell. c) Amplified; more than 2 signals per cell. Two hundred cells in 
triplicate sections per sample were blindly scored by three authors (A.R, E.M, M.P).  CROCC 
staining at the centrosomes was also considered abnormal if showed: 1) a diameter greater than 
twice the diameter of centrosomes present in normal epithelium within the same section; 2) 
excesses of centrioles or longer centrioles;  3) changes in shape, size or perinuclear position. An 
antibody to the centrosome protein gamma-tubulin (clone TU-30, dilution 1:1000) was used to 
counterstain the centrosome (Table 5). The minimal criterion for the identification of a gamma-
tubulin-positive cell in the context of an abnormal staining pattern associated with putative 
centrosome dysfunction, was the detection of two or more punctate, dot-like immunoreactive 
signals, and/or robust diffuse staining, in the cytoplasm of individual tumor cells as previously 
described. 52,53 Thus, signal score was analyzed taking into account  the cytosolic “non-
centrosomal”  and centrosomal  localization  of gamma-tubulin in each tissue section.  Samples 
were also immunostained with the following  markers:  CDX2, CK20, TP53 and SMARCB1/INI1 
and MMR as previously  reported.54 
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Table 5.  Antibodies employed and working conditions for  immunohistochemistry and immunofluorescence  
analysis 
 
 
 
3.13 Double-labeling immunofluorescence analysis. 
FFPE tissue sections derived from RC were immunostained for CROCC and γ-tubulin by 
immunofluorescence as described previously.55 Deparaffinized sections were incubated for 50 min 
in a freshly made PBS, serum,  solution containing 1 mg/ml of sodium borohydride (Sigma-Aldrich, 
Saint-Louis, MO, USA) to decrease the autofluorescence, and subsequently they were rinsed 
extensively with PBS. For double-labeling immunofluorescence studies on histological sections, 
anti-human CROCC polyclonal  antibody and a mouse anti-human γ-tubulin monoclonal antibody 
above described were employed. Secondary fluorochrome conjugated antibodies included anti-
rabbit AlexaFluor 594 and anti-mouse AlexaFluor 488, respectively, and were diluted 1:1000 with 
PBS. Double staining was performed in two sequential sessions of immunofluorescence staining. 
4’,6-diamidino-2-phenylindole (DAPI) was used to label cell nuclei. Slides were cover-slipped 
using an aqueous-based mounting medium (Vector Laboratories, Cambridgeshire, UK). 
Antibody Company Clone Source dilution 
α tubulin ABCAM 18251 rabbit polyclonal 1:100 
β tubulin COVANCE TUJ1 mouse monoclonal 1:500 
γ tubulin ABCAM TU-30 mouse monoclonal 1:100 
CROCC ABCAM NBP1-80820 rabbit polyclonal 1:200 
INI1 BD BAF47 mouse monoclonal 1:50 
γH2AX ABCAM p S139 rabbit polyclonal 1:500 
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3.14 High resolution melting (HRM) analysis  
Loss of heterozygosity (LOH) analysis was done using fluorescent labeled forward primers, 
followed by fragmental analysis detection on Rotor-gene Q 5plex HRM (Qiagen, Hilden, DE).  
DNA from rhabdoid tumor and matched normal samples were analyzed for  LOH at the CROCC 
locus (1p36.13) by using three markers D1S3391, D1S1443, D1S3669. Additional markers at the 
SMARCB1 locus (22q11.2) D22S301 and D22S345 were investigated.56 PCR conditions for the 
multiplex PCR consisted: initial denaturation at 95°C for 15 min, followed by 19 cycles of 95°C 30 
s, 55°C 90s, 72°C 1min, and final extension at 72°C 30 min. PCR reactions were performed in a 10 
μl reaction mixture by using 50 ng template DNA, 0.2 mM dNTPs (Roche, Penzberg, DE), 0.4 U 
FastStart Taq DNA Polymerase (Roche, Penzberg, DE), 1x fluorescent dye LCGreen Plus (Idaho 
Technology, Salt Lake City, UT, USA), 2 mM MgCl2  and forward and reverse primers (0.5 mM 
each) for each gene segment.  PCR conditions were optimized to temperatures between 52°C and 
64°C for each segment. After 30 cycles of amplification, PCR products underwent an additional 1 
min at 98°C and then 5 min at 40°C to promote heteroduplex formation. Each capillary was then 
transferred to the High Resolution Melter instrument (HR-1) (Idaho Technology, Salt Lake City, 
UT, USA) for high resolution melting and curve analysis. Samples were melted at 0.2°C/s ramp 
rate.33 Melting profiles were analyzed with HR-1 software using fluorescence normalization, 
temperature shift and conversion to difference and derivative plots. To confirm the reliability of the 
HRM assay, selected paired non-neoplastic tissue samples showing or not  a difference in melting 
profiles were purified and then sequenced in both directions using the Big Dye Terminator 1.1 
Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA). Sequencing reaction was 
performed on an automatic sequencer ABI PRISM 310 Genetic Analyzer  and sequences were 
analyzed using BioEdit program.57 
3.15 cDNA preparation and quantitative PCR 
Total RNA was isolated from three 10-µm FFPE paired tumour and normal tissue sections per 
patient using RNeasy FFPE Kit (Qiagen, Hilden, DE) according manufactures’ instructions. 
Paraffin was first removed by xylene extraction followed by ethanol wash. A DNase I treatment 
step was included to remove DNA from total nucleic acids.  Reverse transcription was performed 
using the first-strand cDNA synthesis kit (General Electric, Buckinghamshire, UK). qPCR was 
performed in 96-well plates using pre-designed TaqMan probe/primers on a ABI 7900HT system 
(Life technology, Carlsbad, CA, USA). All reactions were performed in duplicate. The relative 
amount of mRNA was calculated using the comparative Ct method after normalization to GAPDH 
or rRNA 18S expression. For RT-qPCR analysis, a total cDNA amount corresponding to 10–50 ng 
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of starting RNA was used for each reaction. Fast SYBR Green Master Mix from Life Technologies 
and 10 μM for each primer pair were used. qPCR reactions were performed on an Applied 
Biosystems 7500 Real-Time PCR machine using the standard amplification protocol. The 
sequences of the specific primers for RT-PCR are listed in (Table 3). RNA purity and quantity were 
measured on a Jenway Genova Plus spectrophotometer (Bibby Scientific, Staffordshire,UK). 
3.16 Protein extraction and immunoblotting  
The Qproteome FFPE Tissue Kit, (Qiagen, Hilden, DE) was used to isolate full-length proteins 
from FFPE tissues according to the manufactures’ instructions. To lyse cultured cells and frozen 
tissues, RIPA buffer  (150 mM NaCl, 1.0% Nonidet P-40 or Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS and 50 mM Tris, pH 8.0) supplemented with protease inhibitor cocktail (Sigma-
Aldrich, Saint-Louis, MO,USA) were used. Next lysates were sonicated using the Bioruptor 
Sonication System (Diagenode, Liège, BE) and then centrifuged at 13,000g for 15 min. Protein 
quantification was performed using the Bradford protein assay (Bio-Rad, Hercules, CA, USA) 
following the manufacturer’s instructions. Protein extracts (50-80 μg per sample) were run on a 
precast NuPAGE 4–12% Bis-Tris Gel (Life technology, Carlsbad, CA, USA) transferred to a 
nitrocellulose membrane and blocked in TBST (50 mM Tris, pH 7.5, 150 mM NaCl and 0.1% 
Tween-20) and 5% milk. Primary and secondary antibodies were diluted in TBST and 5% milk. 
Blots were scanned using a LI-COR Odyssey Infrared Imaging System, and bands were quantified 
using ImageJ software. To normalize protein expression levels, densitometric analysis was carried 
out to housekeeping proteins, beta-actin and tubulin and when required a positive control was also 
used.      
 
3.17 DNA mismatch repair and CIMP analysis  
DNA mismatch repair was analysed through immunohistochemical staining for DNA mismatch 
repair proteins and Microsatellite instability (MSI) molecular tests as already described.54 Briefly, 
detection was performed on tumour and when available adjacent normal tissues.  The antibodies 
used (clones, dilutions, antigen retrieval and manufacturer) included: MLH1 (ESO5, 1:100, Bond 
Epitope Retrieval Solution 2, Novocastra Laboratories, Newcastle, UK); MSH2 (25D12, 1:80, 
Bond Epitope Retrieval Solution 2, Novocastra Laboratories, Newcastle, UK); MSH6 (44, dilution 
1:25, Bond Epitope Retrieval Solution 1, Cell Marque, Rocklin, USA); PMS2 (MRQ-28, 1:20, 
Bond Epitope Retrieval Solution 2, Cell Marque Rocklin, USA); Tumours were defined as 
mismatch repair-proficient whereby neoplastic cells showed nuclear immunopositivity for all four 
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markers. Immunopositive stain was defined as an unequivocal nuclear labelling of the tumour cells 
with staining intensity comparable to that of internal control. Other internal controls were 
represented by positive stromal/lymphoid cells. Inflammatory and stromal cells adjacent to 
neoplastic cells served as positive internal controls.  The tumors were defined as mismatch repair-
deficient when they showed loss of nuclear  “complete absence” staining in at least one of the four 
markers with concurrent positive labelling in internal non-neoplastic tissue. A recurrent positive 
expression for MMR proteins was present in normal crypts, fading out towards the lumen.  MSI 
analysis was performed for the National Cancer Institute recommended microsatellite marker panel 
BAT25, BAT26, D2S123, D5S346, and D17S250 using fluorescently labeled primers on a 3130xl 
Genetic Analyzer (Life technology, Carlsbad, CA, USA). MSI-H was diagnosed if instability was 
evident at 2 or more markers as already described.54 Genomic DNA isolation and sodium bisulphite 
modification were carried out as reported. The converted DNA was subjected to quantitative 
methylation specific PCR as reported. 1,30 The following genes (RUNX3, IGF2, SOCS1, NEUROG1, 
CDKN2A (p16) and hMLH1) with methylation levels greater than 15% were considered positive. 
Tumors with at least three methylated loci were classified as CpG island methylator phenotype 
(CIMP)-positive and the remaining cases as CIMP-negative. The primers for promoter methylation 
analysis have already been reported.6,54 
 
3.18 Interphase fluorescence in situ hybridization (I-FISH)  
Fluorescently Labeled Polynucleotide Probes for alpha-satellites of chromosome 17 centromere 
(CEP17) probe and for the human ERBB2 gene were used as initial screening for detecting 
chromosomal numerical abnormalities in the in the FFPE tumour sections.  The zytolight SPEC 
ERBB2/CEN17 dual color Probe comprehensive of  centromere of chromosome 17 probe 
(ZyOrange: Orange excitation at 547 nm and emission at 572 nm, similar to rhodamine) and 
ERBB2 probe (ZyGreen: excitation at 503nm and emission at 528 nm, similar to FITC) were used 
according to the manufacturer’s recommendations (ZytoVision, Bremerhaven, DE). The slides were 
examined using an Olympus BX61 (Olympus, Hamburg, Germany) with appropriate filters for and 
for DAPI nuclear counterstain.  The alpha-satellite chromosome-specific DNA centromeric probes 
for chromosomes 1 and  12 centromere (CEN1 and CEN12) were used to further investigate 
chromosome number into nuclei of the cells (ZytoVision, Bremerhaven, DE). The results were 
interpreted following enumeration of the signals in 500 interphase nuclei. 
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3.19 In-house control colorectal carcinoma data sets and Tissue Microarrays  
Two independent subsets of patients with primary sporadic colorectal carcinoma (CRC) were 
included in this study and used as control population. CRC tissues including (n=141, stage I-IV, 
cohort A)  and (n=102, stage IV, cohort B) cancer along with the corresponding adjacent non-
involved tissues (n=61) and (n=22) respectively were collected. For both cohorts were available 
FFPE blocks, while, for 80 out of 141 patients of the (Cohort A) were also available snap-frozen 
paired tumour-normal tissues in liquid nitrogen and stored at −80°C. Patients who had a familial 
history of intestinal dysfunction or CRC, had received chemotherapy or radiation before resection 
or had taken non-steroidal anti-inflammatory drugs on a regular basis were not included. For each 
patient, the date of colon cancer diagnosis, date of last follow up, and vital status at last follow-up 
(i.e., living or deceased), Overall Survival (OS) and Progression Free Survival (PFS) were recorded. 
The latest update was performed on May 1st, 2015. The main clinical-pathologic features of all 
patients are summarized in (Tables 6,7). Colon cancer tissue microarrays  TMAs fully annotated 
with clinical and pathological information were obtained from the two data sets and screened for 
markers of colon epithelial differentiation (CDX2, CK20, TP53), mismatch repair proteins 
(MMR)(MLH1, MSH2, MSH6 and PMS2) and genetic KRAS and BRAFV600E mutation status. 
TMAs  were assembled as already described.29,54 Briefly, Cores measuring 0.6 mm in diameter 
were made in triplicate from paraffin blocks comprising tumor tissues or matched normal mucosa 
and processed using the ATA-27 automated arrayer (Estigen, Tartu,EW). H&E from TMA were 
reviewed to ensure that from each case were morphologically similar to those of the corresponding 
whole tissue section and represented cancerous or normal epithelial cells. All FFPE blocks, frozen 
tissue and TMA were analyzed. 
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Table 6. Correlation between CROCC IHC, Clinicopathologic and molecular features of 140 colorectal 
cancers Stage I-IV.  
 
 
 
 
 
Abbreviations: Right includes: Proximal caecum, ascending and transverse colon. Left includes: Distal 
descending, sigmoid colon, rectum. ADC adenocarcinoma, ADC-Muc adenocarcinoma with a mucinous 
component below 50%.   Tumors deficient or proficient in DNA mismatch repair (MMR) were identified 
based on detection of MLH1, MSH2, PMS2 and MSH6 proteins. CROCC expression by IHC was calculated 
as follows: the number of visible centrosomes was counted on (>200 cells), and expressed as loss (< 1 
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centrosome per cell); Normal (from 1 to 2 centrosome per cell) or amplified (more than two centrosomes per 
cell). 
 
Table 7: 102 metastatic Colorectal cancer tissue microarrays investigated by 
immnohistochemical staining.  
 
 
 
 
Abbreviations: others metastatic sites include (Peritoneum, Lymphonodes, Bone, CNS). Tumors deficient 
or proficient in DNA mismatch repair (MMR) were identified based on detection of MLH1, MSH2, and 
MSH6 proteins 
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3.20 Cell culture 
Human colon cancer cell lines HCT116, HT29, CaCo-2, LoVo, RKO, T84, DLD1, SW480 and 
SW620 were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA) and 
cultured as appropriate at 37 °C in 5 % CO2 atmosphere in Dulbecco’s modified Eagle’s medium, 
DMEM (Thermo fisher scientific, Whaltam, MA, USA) or RPMI 1640, (Thermo fisher scientific, 
Whaltam, MA, USA)  supplemented with 10 % fetal bovine serum (FBS) or when required without 
FBS, 100 U/ml penicillin and 100 ng/ml streptomycin (Thermo fisher scientific, Whaltam, MA, 
USA). BJ human skin fibroblasts derived from normal foreskin and G401 cells derived from 
pediatric rhabdoid tumor were maintained in DMEM and RPMI 1640 medium, respectively, 
supplemented with 10 % fetal bovine serum (FBS), 1 mg/mL penicillin, 1 mg/mL streptomycin in a 
humidified incubator at 37 °C and 5% CO2. All cell lines were tested with the mycoAlert 
Mycoplasma Detection Kit (Lonza Walkersville, Walkersville, MD, USA) and found to be free of 
mycoplasma. The genotype of parental cell lines were confirmed by short tandem repeat (STR) 
genotyping. The STR genotypes were consistent with published genotypes for each cell lines. All 
cell lines were found to be free of mycoplasma tested with the mycoAlert Mycoplasma Detection 
Kit (Lonza, Basel, Switzerland).   
3.21 Plasmid transfection 
The RKO cells at 70-80 % confluence was transiently transfected with SureSilencing control or 
CROCC shRNA expression plasmids (KH23140P, (Qiagen, Hilden, DE) containing the puromycin 
resistance cassette. Transfected cells were selected with 0.8 μg/ml puromycin (Thermo fisher 
scientific, Whaltam, MA, USA) for 1 week and single colonies were amplified and assessed for 
efficient CROCC silencing by semiquantitative and quantitative PCR (qPCR).  For rescue 
experiment, the full-length CROCC coding sequence “clone 6150861 pEGFP Rootletin, Nigg 
pFL2(CW499)” gift from Erich Nigg or a truncate form (1–494aa) cloned with GFP epitope or GFP 
alone (used as control) were transfected in metastatic T84 cells and selected in 2 mg/ml G418 
before flow-sorting CROCC-GFP expression.58 Cell vitality for long-term experiments CROCC-
GFP+ cells were maintained in 0.6 mg/ml G418. All transfections were performed with 
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Lipofectamine 3000 (Thermo fisher scientific, Whaltam, MA, USA)  according to the 
manufacturers’ recommendations.  
3.22 Metaphase spreads and clonal FISH preparation 
For metaphase spreads, CRC cells were collected after 1-h treatment with 10mM colcemid Gibco® 
KaryoMAX® Colcemid™ (Life technology, Carlsbad, CA, USA), (Gibco), and swelled with KCl 
(0.4%, 37 °C, 7 min) before fixation in 3:1 methanol:acetic acid. Cells were dropped onto glass 
slides and aged for,2 weeks. For clonal FISH, 500 cells were expanded into colonies of 30–60 cells 
on glass slides before KCl treatment and fixation in 3:1 methanol:acetic acid. Slides were denatured 
(70 uC in 23 sodium citrate (SSC)/75% formamide, 2 min, quenched in ice-cold 70% ethanol) and 
dehydrated through an ethanol series. Chromosome specific Alpha-satellite repetitive centromere 
DNA for chromosome 1 and X, respectively were used (CEP1, CEPX Abbott, Abbott Park, IL, 
USA). The probes were denatured (90 uC, 6 min) and hybridized to slides (16 h, 37°C), and then 
washed. Slides were dehydrated and mounted in Vectashield hardset plus DAPI mounting medium 
(H-1500).    
3.23 Nocodazole washout assay 
Cells were then incubated for 5, 15 and 30 min with the microtubule destabilizer nocodazole (10 
μg/ml) at 37°C, washed five times with PBS at room temperature. To determine recovery times, 
slides were then fixed in -20°C methanol. Microtubule structures were detected using antibodies 
described above against anti–gamma-tubulin (1:500 in 1% BSA for 1 hr) and/or CROCC (1:200 in 
1% BSA for 1 hr). The primary antibody was detected with an FITC labeled sheep antimouse 
antibody (1:500, 1 hr, Sigma-Aldrich, Saint-Louis, MO, USA) and cells counterstained with 
propidium iodide. Asters were counted when clear signals at the periphery of the nucleus were 
detected. The completion of microtubule regrowth was scored when the pattern of 
immunofluorescence resembled the one prior to the nocodazole induced depolymerization.  The 
amount of time required for the reformation of microtubules from the endogenous tubulin was 
assessed for normal human fibroblasts, BJ cells used as control.  
3.24 Immunofluorescence on CRC cell lines  
Cells grown on coverslips were rinsed in PBS and fixed with 4% paraformaldehyde at room 
temperature for 20 min. After rinsing with PBS, they were incubated with 0.1% Triton X-100 at 
room temperature for 10 min to permeabilize the cell membrane and rinsed again with PBS. Cells 
were incubated in blocking solution (6% BSA in PBS) for 1 h at room temperature and then with 
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primary antibody overnight at 48C. The primary antibodies were rabbit polyclonal or mouse 
monoclonal anti-γ-tubulin,α-tubulin and CROCC as for immunohistochemistry. The slides were 
rinsed three times with PBS and incubated for 1 h at room temperature with secondary 
fluorochrome-conjugated antibodies anti-rabbit AlexaFluor 594 and anti-mouse AlexaFluor 488, 
respectively. DAPI was used to label cell nuclei. The preparations were mounted with Vectashield 
mounting medium (Vector Laboratories, Burlingame, CA, USA) and examined with an Olympus 
IX81 deconvolution fluorescence microscope (Olympus Microscopes, Center Valley, PA). No 
staining was detected when conjugates alone were used as negative controls. Alternatively, cells 
grown on coverlips were fixed in cold methanol and double-label stained with monoclonal anti-γ-
tubulin and anti-CROCC or  in addition anti-γ-tubulin anti-α-tubulin antibodies. A secondary anti-
mouse antibody, conjugated with Cy3, and an anti-rabbit antibody, conjugated with FITC, were 
diluted 1:500, 1:1000 respectively. 
3.25 Immunoblotting   
Briefly, protein extracts from cell lines and tissue sections of fresh tissue specimens from tumour 
and matched normal adjacent mucosa frozen in liquid nitrogen were prepared and analyzed as 
previously reported.54 The primary antibodies included those described above; CROCC, gamma-
tubulin, beta-tubulin, β-actin and  SMARCB1 (H300, Santa Cruz, Dallas TX, USA). The secondary 
antibodies were used anti-mouse (sc-2031) and anti rabbit (sc-2004) (Santa Cruz, Dallas TX, USA).  
3.26 CAsy cell counter and Proliferation assay 
Cell number and density of viable cells were determined using CAsy Cell Counter (Roche Innovatis 
AG, Reutlingen, DE). Each sample (cell suspension) was prepared three times in CAsyTon buffer 
(Roche Innovatis AG, Reutlingen, DE), followed by triplicate measurements of 200 μl sample 
volume. All counts of a size smaller than 10 μm (dead cells and debris) were excluded. For cell 
proliferation assay, 5,000 cells/well were seeded in 96-well plates. The number of proliferating cells 
was evaluated by 3-(4,5-dimethyl-2- thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT). At the 
indicated times, MTT solution (Sigma-Aldrich, Saint-Louis, MO, USA)  in complete medium 
(0.28-mg/ml final concentration) was added and incubated at 37°C for 4 h. The medium was 
discarded, and the formazan salts were dissolved in 4 mM HCl, 0.1% NP40 in isopropanol. The 
colorimetric substrate was measured and quantified at 560 nm in an enzyme-linked immunosorbent 
assay plate reader. 
3.27 Cell morphology, wound healing and invasion assay  
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Initially, cell motility was evaluated by the wound-healing assay. Briefly, cells were grown to 
confluence and a wound made through the monolayer using a p1000 tip. Accurate measures of the 
wounds were taken during the time course to calculate the migration rate according to the equation: 
percentage wound healing = ((wound length at 0 h) - (wound length at 24, 48 or 72 h))/(wound 
length at 0 h) x 100. Phase-contrast images were acquired every 2 h for 24 h and the percentage of 
migrating cells was determined automatically. Three independent experiments were performed. For 
invasion assay, 2 × 104 cells were added to the upper compartment of a 24-well BioCoat Matrigel 
Invasion Chamber (Corning Incorporated, Tewksbury, MA, USA) in serum-free DMEM. After 24 
h, invading cells were fixed, stained with crystal violet 0.1% and counted. Hematoxylin&Eosin 
staining was used to reveal morphological changes in CRC cells under investigation. 
3.28 Cell cycle and Flow cytometry analysis 
Cell cycle analysis was performed three days after seeding on both attached and floating cells using 
the BD Cycletest Plus DNA reagent Kit (Cat. No. 340242; (BD Biosciences San Jose, CA, USA). 
Propidium Iodide stained cells (>20.000 events) were analyzed by flow cytometry on FACSVerse 
(BD Biosciences San Jose, CA, USA). Debris and doublet cells were excluded and only single cells 
were considered for cell cycle analysis. Results were reported as percentage of cells in G1, S and 
G2/M phases. All flow cytometry results were analyzed with the FACSuite Software v.1.0.5.3841 
(BD Biosciences San Jose, CA, USA). Four biological replicates were prepared and each assayed in 
triplicate; the results were reported as mean ± standard deviation (SD).   
3.29 Statistics 
Patient subsets were compared for survival outcomes, using both Kaplan-Meier survival curves and 
multivariate analyses based on the Cox proportional hazards method. Differences in Kaplan-Meier 
curves were tested for statistical significance using the log-rank test even once stratified based on 
gene or protein expression patterns. For meta-analysis on the rhabdoid colorectal cancer,  data from 
19 reports in the literature were compiled. This resulted identification of a total of 23 patients for 
whom  follow-up and some molecular data were available for 20 and 9 patients, respectively (Table 
8). Life table analysis was performed in order to provide Kaplan-Meier estimates of survival after 
stratification separately for clinicopathological factors. Differences in survival among subgroups 
were analyzed using a Cox proportional hazards analysis on other variables. Relative risks of death, 
ratio of mortality rates between subgroups, were estimated from the Cox regression model with and 
without adjustment for other factors.  Progression Free Survival (PFS) was compared between the 
groups when available and defined as the time elapsed between the start of first line chemotherapy 
36 
 
and disease progression, treatment discontinuation or death. Overall Survival (OS) was defined as 
the time elapsed between the start of first line chemotherapy and death.  The pattern of gene 
expression profile (GEP) in independent data sets “TCGA pooled series” of  patients was  analyzed 
as previously reported.54,59 The presence of an enrichment defined tumors subtypes characterized by 
high pathological grade (G3/G4), microsatellite, instability (MSI) or gene mutations was tested 
using Pearson’s t-test and by computing odds-ratios (OR) together with their 95% confidence 
intervals (CI). Differences in the expression levels of individual genes or other markers among 
different sample subgroups  were evaluated using boxplots and tested for statistical significance 
using a 2-sample t-test (2-tailed). Patients with documented follow-up were also available for 
survival analysis. We censored those patients who were alive without tumor recurrence or dead at 
last contact. Wilcoxon-Mann-Whitney and Kruskal-Wallis tests with median differences at 95% 
confidence interval (CI). The Spearman rank test was used to assess the correlation between 
continuous variables, and the Pearson X2 test for the association between categorical variables. Data 
are presented with mean, medians and ranges. The P values were calculated two sided. Statistical 
analyses were conducted were performed by GeneSpring R/bioconductor v.12.5 and R based 
package, SPSS (version 15 Windows, SPSS Inc, Chicago, IL), and GraphPad Prism 5.   
 
Table 8. Rhabdoid colorectal cancer reported in literature between 1993-2015 
 
 
Number Case Age Sex Location metastasis type survival (m) 
(BRAF, 
KRAS and 
MMR) 
 
SMARCB1 
(IHC) 
1 Baba 45 F ? ? ? 1.5 ND ND 
2 Romera 77 M DC no pure 2 ND ND 
3 chetty 72 F Cecum yes composite ? ND ND 
4 Yang 75 M Colon no pure 0.5 ND ND 
5 markus 84 F Colon No composite ? alive ND ND 
6 Nakamura 76 M Cecum yes pure 2 ND ND 
7 Kono 66 M Cecum no composite 1.5 ND ND 
8 Mastoraki 62 F Colon yes pure 4 ND ND 
9 Seok 63 M Cecum yes pure ? ND ND 
10 Hoon-kuy 69 F Sigmoid no composite 6 ND ND 
11 Lee 62 M Sigmoid no composite 36  alive ND ND 
12 Lee 83 M Rectum yes composite 1 ND ND 
13 Agaimy 79 M Cecum no composite 6 Yes (BRAF/D) Neg 
14 kalyan 31 F Cecum yes composite 4 Yes (KRAS/P) ++ 
15 Remo 73 F Cecum no composite 6 Yes (BRAF/D) Neg 
16 Pancione 71 F Cecum yes pure 8 Yes (BRAF/D) ++ 
17 Stulpinas 49 M Rectum yes composite 7 Yes (BRAF/P) ++ 
18 Moussaly 87 F Transverse no composite 2 ND ND 
19 Cho 73 M Cecum no composite 1 alive ND ND 
20 Sanchez 77 M Transverse no pure 2 Yes (WT/P) ND 
21 Sanchez 65 M Descending no pure 12 alive Yes (WT/P) ND 
22 Sanchez 63 M Descending no pure 1 Yes (KRAS/P) ++ 
23 Sanchez 71 F Cecum no composite 8 Yes (BRAF/D) ++ 
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All RC reported are characterized by loss of CK20 and positivity for Vimentin  (IHC). 
Molecular test BRAF (V600E), KRAS, MMR: ND: Not Done (14/23=60%);   
Location: cecum: (10/23=43%) 
Type: composite; (13/23= 56%) 
MMR= D, Defective; P, Proficient 
 
4 Results 
4.1 Identification of CROCC mutations in two rare rhabdoid colorectal cancers.    
To decipher the molecular pathogenesis of these disease entities, two rare cases of primary RCs 
(RCI and RCII) harboring MSI due to MLH1 promoter methylation, CIMP, BRAF V600E mutation 
and wild type SMARCB1 6,19 were subjected to whole exome sequencing (WES) using DNA from 
formalin-fixed-paraffin embedded matched tumor/normal samples.  Consistent with MMR defects 
but not with genomic profiling of the ERTs, we detected an exceptionally large number of somatic 
point mutations 1056 and 1078 per 106 bases for RCI and RCII, respectively (Figure 1). 41,60,61   
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Figure 1. Whole exome sequencing reveals  CROCC  mutations  in two patients with rhabdoid 
colorectal  cancer. 
Representative  H&E  pictures  of  two  rare  rhabdoid  colorectal cancer  specimens  (RCI  and  RCII  
patients)  sequenced  by  whole  exome  sequencing.  The  upper  graph  indicates  the  total  number  of  
somatic  mutations per tumor. The distribution of non-silent single nucleo tide variants (blue), and other 
common non- silent  mutations  splicing  (green) stop  gain (red) are shown using  circos. The  outer rings are 
chromosomes,  the next ring depicts copy number (red represents gain and g reen represents loss) 
 
The distribution of somatic substitutions showed a higher rate of transitions as compared to 
transversions (71.8% vs 28.2%)  with a dominance of C>T/G>A, T>C/A>G transitions.  About 1/5 
of mutations occurred within CpG dinucleotide context as has been seen in other  classical 
colorectal cancers (CRCs).41,61 The relatively elevated frequency of C>G/G>C and C>A/G>T 
transversions also supported a mutational signature involving DNA repair mechanisms other than 
hMLH1 deficiency( data not show). However, as has been found in most MMR defective tumor 
types, the most prevalent single nucleotide variants (SNVs) were non-silent mutations41, whereas, 
over 90% of potentially damaging mutations were missense and around 10% were splicing, stop-
gain, stop-loss or rarely frameshift insertions or initiation codon mutations (Figure2A).  
We identified 112 (10%) shared protein-coding mutations which enriched biological processes of 
relevance to the hallmark phenotypes (Figure 2B). 
 
 
 
 
 
 
 
Figure 2 mutational analysis. A)Number and type of mutations reported in RC1 and RC2. B) shared 
protein-coding mutations 
 
By applying a bioinformatics tool, “DrGaP”, 23  to the shared somatic mutations, we found 20 
potential candidate disease-causing genes, of which nearly half (45%) were related to 
cytoskeleton/centrosome and microtubule biological functions (Figure 3) 
 COMMON SOMATIC MUTATIONS 
        RCII      RCI 
A B 
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Figure 3. Recurrence of twenty shared  potential  diseases-causing  genes  in  (n=630)  colorectal  
cancer  TCGA  database 
. 
 The search in public TCGA database41,61,62 comprising 630 classical CRC 
(http://www.cbioportal.org), revealed that the majority (13 out of 20; 65%) of the 20 candidate 
genes had low frequency  of mutations (≤4% of cases) and strikingly among these, only one 
candidate CROCC “rootletin” 58, a centrosome linker gene mapping to 1p36.13 was notable, 
because no somatic mutations (0/630; 0%) were reported. We discovered two missense mutations in 
CROCC, p.Ala161Ser (c.481G>T, Exon 4) and p.Val1885Ala (c.5654T>C, Exon 35), and one 
remarkable splicing mutation (c.3705-2A>G) at the conserved 3’ acceptor splice site in the intron 
between exons 25-26 (Figure 4).   
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Fig4. chromosome  localization  (1p36.13)  and  organization  of  CROCC or  “rootletin” 
All exons 37, are depicted as green  vertical bars and introns as horizontal  lines. Solid circles  indicate    
mutations    identified  in  two  RCs. CROCC  forms  the  structural  basis  of  centriole-centriole cohesion  
system “proteinaceous  linker”  black  arrowhead. Centrosome  consists  of  two  pairs  of  centrioles 
daughter  centriole  and  mother  centriole    surrounded  by  the  pericentriolar  material  (PCM).  Before  
mitotic entry, the fibrous “proteinaceous linker” is degraded through mitotic kinases to allow centrosome 
separation and  define  the  opposite  spindle  poles  for  mitotic  spindle  assembly  (M) 
 
Notably, the splicing mutation verified by sanger sequencing in patient (RCI), reduced the strength 
of the physiologic acceptor site, predicting a large deletion of the CROCC coding region (-32.51% 
of the wild-type) involving  exons 23-31 (data not show). Next, RT-PCR amplifications “spanning 
CROCC-exons 5–7 and 33-35”  were carried out using cDNA from the paired tumor-normal 
mucosa. The tumor bearing spicing mutation, exhibited low CROCC mRNA and protein expression 
which prevented us from building a exon junction map, then indicating alteration of the mature 
transcript by the utilization of cryptic splice sites or by the activation of the nonsense-mediated 
mRNA decay pathway, which impair transcripts harboring large deletions63 (Figure 5).  
                                            
 
                                                                                      
Fig5 Patient-matched  tumor-normal expression quantification of CROCC mRNA (A) identifies consistent, 
downexpression in all seven RCs.  *P <  0.01  derived  from    two-tailed  Student’s t test  for  each  patient. 
(B) In  normal  colon  epithelia CROCC  labeling reveals round and uniform in size centrosomes, whereas in 
rhabdoid cells centrosomes  are  reduced  in  number  or  display  profound  alterations  resulting  in  
mispositioned  or  larger centrosomes  into  anucleated  cells, “inset  modeled  image” 
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Patient-matched tumor-normal expression from individual RCII, harboring the missense mutation 
(c.5654T>C) also confirmed the previous observation with lower CROCC expression levels in 
tumor than in normal tissue (data not show). The screening across major cancer types revealed that 
de novo mutations in the CROCC gene were poorly represented across NCBI/TCGA database, 
whereas, the majority of tumors including  pediatric rhabdoid derived cell lines64 displayed 
recurrent overexpression of CROCC (45%, 9 out of 20)  and a few of genetic deletion at 1p36.13 
locus (10%, 2 out of 20) .61 By contrast, we found recurrent copy number loss at 1p36.13 locus65 in 
neuroblastoma (65%, 11 out of 17) and in a small but relevant proportion of aneuploid “MSS” 
(23.6%, 9 of 38) colon cancer cells than in non-aneuploid “MSI” (4.5%, 1 out of 22. Compared to 
CRC cells retaining 1p36.13, those harboring the deletion revealed a gene-expression signature 
significantly enriched for pathways implicated in chromosomal instability66,67,68(data not show). 
Thus, we suspected that deleterious mutations affecting CROCC at the centrosome underlie RC 
pathogenesis in two patients. 
 
4.2 Consequences of CROCC dysfunction in rhabdoid tumors. 
In an effort to analyze the significance of the mutations identified in the discovery screen on the two 
cases, we collected further five patients with RC, thus a total of 7 cases (4 males and 3 women, 
mean age 67 years) were studied (Table 1).  Notably, across the five RCs, we did not identify 
additional mutations in CROCC but loss of heterozygosity (LOH) at the 1p36.13 locus associated to 
mRNA reduction, below normal levels in all cases (Fig. 6 and Table 1).  
 
 
 
 
 
 
Fig 6. loss of heterozygosity analysis (LOH) at the 1p36.13 locus in rhabdoid colorectal cancer  
 
 
These results suggested recurrent lack of CROCC expression as a consequence of the loss-of-
function in the wild-type allele65. The majority of the RCs  revealed BRAFV600E mutation, CIMP and 
LOH 
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a wild-type SMARCB1, while, “3 out of 7 tumors” had MSI associated with promoter 
hypermethylation of MLH1, and  the remaining 4 cases were MSS or mismatch repair–proficient 
tumors (Table 1). We next aimed to determine the level of mitotic aberrations and found that all 
RCs displayed a high prevalence of bizarre mitotic figures, prevalently segmented/multi-lobular 
nuclei or aberrant enucleated cells and a variable degree of cytomorphologic and ploidy aberrations 
such as triploid or near-tetraploid cells ranging from 10% to 40% of tumor cells (Figure7).  
 
 
 
 
 
Figure7. from the left,  representative  microphotographs  including anucleated  cells, cytomorphologic  
aberrations(a)  including  multi lobulated  nuclei(b), abnormal  mitotic  figures  (c), tripolar mitosis(d), 
mitotic catastrophe with  fragmented  chromatin(e)  
 
 
Compared to our dataset of RCs, genetic profile of seven ERTs hereafter named (RI), revealed 
predominant  missense or truncating mutations in SMARCB1 (5/7, 71%), 15 or in  TP53 (3/7, 42%) a 
near diploid DNA content18  and less aggressive clinical course .6-11 (table 9) 
 
 
 
 
Table 9. Infants/young adults rhabdoid cancers of the central nervous system: clinicopathological and 
immunohistochemical features of the 7 cases. 
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We therefore conclude  that RCs although morphologically indistinguishable from their pediatric 
counterparts demonstrate  distinct molecular and  cytogenetic aberrations. We next determined the 
consequences of the genetic alterations on the CROCC protein using paired non-tumor tissues as 
control. Immunohistochemical analysis on RCs, revealed tumor cells with no CROCC labeling 
(nearly 50%), cells with a single and often incorrectly positioned and/or fragmented positive 
centrosome with most having bizarre phenotypic defects, for example, enucleated cells harboring a 
large and single centrosome in the late telophase (Figure 5b). The study of γ-tubulin labeling as 
reference marker to centrosome58,69 revealed either a diffuse accumulation into cytoplasmic 
fraction52 often accompanied by a single centrosome or lack of centrosome staining (~50% of cells) 
(Figure 8).  
 
 
 
                                      
              
  
                     
               
                                                                                   
 
Figure8:  γ-tubulin labeling of rhabdoid colorectal cancer tissue  a) immunofluorescence merge of crocc 
(green) and γ-tubulin (red) show a single big centrosome. b) immunohistochemistry of γ-tubulin on two 
cases of rhabdoid colorectal cancer show mitosis monopolar with single centrosome 
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In contrast, the large majority of RI predominantly had a single or pair CROCC-positive 
centrosome (80%) often closer to the nucleus than RCs, but considerably larger, and  only (10%) 
were cells with no centrosome. Compared to RCs, analysis of labeled centrosomes was associated 
with much higher tumor/normal paired expression of CROCC (P<0.00001) (Figure.9).  
 
 
 
                                                                        
Figure9 A)Larger  centrosomes  (~1  per  cell)  close  to  the nucleus  marked by CROCC, are  characteristic  
of  pediatric rhabdoid tumors. B)Matched tumor-normal CROCC  mRNA expression level shows significant 
differences between rhabdoid colorectal cancer (RC) and pediatric cases (RI), P value was obtained by 
Mann–Whitney test. 
 
 
 
 
Consistently, we found that CROCC expression levels tended to be either unchanged or 
significantly higher also in a substantial proportion of 140 classical CRCs than in 62 normal 
matched  normal mucosa. Immunohistochemical analysis from the same data set, revealed 
predominantly centrosomes either in normal number (1/2 per cell, 58.5%) but larger in diameter or 
often supernumerary1,3 (>2 per cell, 38%) than those in normal epithelium, while only (<1 per cell, 
3.5%) were tumors lacking centrosomes staining. This latter subgroup  compared to tumors with 
normal or supernumerary centrosomes, was not associated with overall survival HR=1.28; 95% CI 
(0.265-6.23); P= 0.754. We also detected a higher percentage of CRCs with supernumerary (50%) 
or defective (12%)  compared to normal centrosomes (38%; P=0.001) in an independent data set 
comprising 102 patients with metastatic colorectal cancer. In this dataset, tumors harboring CROCC 
deficiency were associated with poorer clinical course than those expressing normal or 
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supernumerary centrosomes (HR=0.30; 95% CI (0.21-0.81); P<0.0001. Overexpression of CROCC 
in CRC was independently validated by querying  publically available TCGA mRNA expression 
data. Although CROCC expression was not related with tumor stage and  overall survival, we found  
consistently higher levels in MSI than MSS tumors. However, extended analysis from TCGA 
database also revealed a few of genomic structural variations (15/616; 2.43%) with a preference for 
copy number gain at the 1p36.13 locus. Thus, CROCC deficiency caused by de novo somatic 
mutations or copy number loss are recurrent in RCs but not in related cancers lacking CROCC 
alterations.  
 
4.3 Functional CROCC depletion impairs mitosis and induces rhabdoid phenotype.  
In line with findings in CRC dataset, CROCC mRNA and protein expression levels, were 
concordant and significantly higher in MSI cells than in MSS “aneuploid” cell lines (P<0.05, Fig. 
10). Notably, all microsatellite unstable cells contained centrosomes stained for CROCC and γ-
tubulin that were functionally and structurally indistinguishable from those in normal human 
fibroblasts BJ.70   
 
 
 
 
 
 
 
 
MSS MSI 
P=0.011 P=0.043 
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Fig10) Quantitative  RT-PCR  amplification  of CROCC  mRNA    into    MSS  versus  MSI  subgroup  
colorectal  cancer cell lines. RT-PCR analysis  was  normalized to rRNA 18S. P  value was  derived from 
two-tailed  Student’s t test.    Inverse  correlation between CROCC and γ -tubulin  quantification  related to 
ȕ-tubulin  by  western-blot analysis  in  a  panel  of  eight  cancer  cell  lines  classified  as  MSS  (red)  
versus  MSI  (green).  The  P  value  was derived from Spearman r correlation. Low, immuno-blot analysis 
showing CROCC and Ȗ-tubulin together in representative  cancer  cell  lines 
 
 
 
Although MSS cancer cells, have an increased frequency of micronuclei, prometaphase DNA 
damage “nuclear γH2AX foci” compared to MSI, we did not detect in any of these cell lines 
chromosome segregation errors resulting in gross mitotic defect67,70 . Therefore, we reasoned that 
RKO cells “MSI” having a near-diploid karyotype and shared gatekeeper molecular alterations 
(BRAF V600E mutation, CIMP)  with RC patients, could be an useful system to explore compromised 
CROCC function in vitro. We found that the clone sh4, hereafter named  (CROCCKD) provided a 
stable and consistent knockdown of CROCC transcript to more than 75% and protein to 3.3-fold 
lower then RKO cells transfected with control vector (shCon) achieving nearly comparable levels to 
those seen in vivo (Figure 11).  
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Figure 11. CROCC  silencing  was  performed  by  transfecting  into  RKO  a  pool  of  short-hairpin 
(shRNA)  plasmids  (sh1-4)  targeting  different  region  of  the CROCC  gene  or  a  control  shRNA  
plasmid  for nonspecific off-target effect (shCon). Selected cells were assessed for CROCC silencing by 
semiquantitative RT-PCRand the most efficient (sh4 clone) by western blot analysis. 
CROCC depletion caused aberrant mitotic divisions resulting in a higher frequency of monopolar 
spindles and incorrectly aligned chromosomes as compared to control. During metaphase,  we 
observed prominent monopolar spindles with a single large centrosome or with structurally 
compromised “fragmented” centrosomes, which  accounted for 85% of the abnormal phenotype 
(Figure 12).  
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Fig 12) CROCC is stably silenced  in mismatch repair deficient RKO cells using short interfering RNA 
knockdown (CROCC KD). shControl (Control) denotes a non-targeting siRNA control. siRNA-mediated 
CROCC depletion leads to abnormal spindle formation “misoriented or large monopolar spindles” as 
compared to control (left panel of images).  During mitosis, the monopolar spindles can be subdivided into 
spindles that had one large or fragmented centrosome. (see supplementary figures). Cells stained for 
microtubules (α-tubulin), centrioles (γ-tubulin, CROCC) and DNA (dapi) are indicated. Schematic of a 
bipolar wild-type spindle and the breakdown of the two abnormal spindle phenotypes seen upon CROCC 
depletion accounting for 85% of the abnormal phenotype. 
 
 
Consistently, an  increased frequency of micronuclei (median 11% CROCCKD versus 1% ShCon 
cells P=0.0003) and γH2AX nuclear foci (median 43 %  CROCCKD versus 18% ShCon cells 
P=0.011,  was observed. Metaphase karyotyping revealed that CROCC deficiency leads to an 
increased number of tetraploid (4N) cells (median 13.3% CROCCKD versus 3.51% ShCon cells 
P=0.001) characterized by prominent and larger nuclei than diploid cells (2N). Consistently, 
analysis of centromeric probes in intephase nuclei confirmed tetraploidy. (Figure 13) 
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Figure 13. CROCC depletion induces rhabdoid phenotype exacerbating mitotic splindle DNA 
segregation errors through tetraploidy  in colorectal cancer Percentage of DNA segregation errors 
accounted for by micronuclei and monopolar spindles. P values were obtained by Mann–Whitney test. 
Representative images of metaphase chromosome spreads of shCon and CROCC KD.  Right panels denote 
example images in cells stained with anti-centromere antibodies (ACAs) and with the 49,6-diamidino-2-
phenylindole (DAPI). and Scale bar, 10 µm. On the left, quantification of chromosome number by 
karyotyping cells (26 chromosome spreads were quantified in each condition). On the right, tetraploid on 
diploid cells ratio is shown. Error bars represent mean ± s.e. The ***P<0.001 and **P<0.01 were derived 
from two-tailed Student’s t-test. 
 
 
Moreover, the number of CROCC-deficient cells was extremely reduced in G0/G1 or G2/M phases 
when compared to the wild-type population (by 26–45%, FACS analysis). By contrast, fasting 
cycles (without FBS) resulted in higher proliferation rate of CROCC-deficient cells than control (by 
more than 50% at 72h), suggesting an impaired cell cycle progression as a consequence of mitotic 
replication stress or misaligned chromosomes.67,71 Most strikingly, CROCC-deficient cells exhibited 
all cardinal signs of  rhabdoid features, displaying huge nuclei pushed to the periphery of the cells 
with single or multiple large nucleoli associated with eosinophilic cytoplasmic inclusions and large 
cellular protrusions resembling morphology observed in vivo. These features  resulted in dramatic 
changes of spindle-shaped morphology, activation of prometastatic genes4,29 and enhanced 
metastatic potential which recapitulated the molecular phenotype seen in patients(Fig 14). Together, 
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these data show that rhabdoid phenotype underlie CROCC deficiency in BRAF-mutated colon 
cancer.  
 
                                       
Fig 14 Proliferation of CROCC KD and control cells subjected to FBS (10%) supplementation or to fasting 
cycles “without FBS”. The *P≤0.05, **P<0.01 and  ***P<0.001 were derived from two-tailed Student’s t-
test. The graphs show mean values and standard deviation of five repeats. CROCC-depleted  and control 
cells stained for hematoxylin and eosin (H&E); black arrow point to characteristic rhabdoid-like features 
with large polygonal cells and eccentric round nuclei with prominent nucleoli in CROCC KD cells. Red 
arrow point to typical eosinophilic hyaline cytoplasmic inclusions of malignant cells with rhabdoid-like 
features. Morphology of control cells are reported.  
 
 
4.4 CROCC restoration suppresses growth in a metastatic model harboring 1p36.13 allelic loss 
To test the hypothesis that CROCC impacts tumor growth and centrosome-related mitotic errors, we 
analyzed T84 CRC cells predict to exhibit copy-number loss at 1p36.13 locus and a high metastatic potential  
as being derived from a lung metastasis.67 Indeed, we found recurrent “monopolar spindles”, tetraploid or 
near-tetraploid cells, and an increased rate of micronuclei consistent with reduced CROCC endogenous 
activity, many of which were dramatically augmented in growth starvation cycles then overlapping CROCC-
knockdown cells. In these latter conditions, immunofluorescence for CROCC revealed a proportion of cells 
either negative (40%) or displaying a single (30%) or fragmented centrosome (10%) in interphase not 
properly overlapping with γ-tubulin localization. Most strikingly, such aberrations were rarely, if ever, 
detected across pediatric rhabdoid G401, colon cancer retai50ning 1p36.13 locus or BJ cells.  Therefore, we 
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transfected CROCC-GFP-tagged (1–2018aa) into T84 cells.24 Unexpectedly, restoration of CROCC, showed 
a dramatic decrease of cell viability (12 days later, 0%) as compared to control plasmid, GFP alone. 
Similarly, the colony formation assay after 10 days,  showed a robustly induced 7-fold fewer colonies than 
those transfected with a control (data not shown). Moreover, gain of CROCC conferred a flat/adherent 
phenotype and formation of filament-like structures co-localizing with γ-tubulin resulting in a profound actin 
cytoskeleton reorganization and lower expression of prometastatic and centrosome-related genes then control 
(Figure 15 A,B).4   
                     
 
 
 
 
50 aA 
50 aB 
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Figure 15. CROCC rescue corrects mitotic errors in a colorectal cancer  harboring  1p36.13 allelic loss. 
A) T84 colorectal cancer cells exhibit copy-number loss at 1p36.13 CROCC locus by in silico prediction. 
Deletion at the 1p36.13 locus induces  loss of CROCC mRNA expression as compared to pediatric-rhabdoid-
derived G401 cells or normal human cells, foreskin fibroblasts (BJ) with intact 1p36.13 locus. Percentage of 
segregation errors taking into account micronuclei and monopolar spindle defects, centrosome defects, 
chromosomal ploidy and mutated tumor suppressors in T84 and G401 cells (n>100 per cell line). B) Images 
of micronucleated cells stained for CROCC (green, enlarged in insets) and DNA (blue, dapi) in T84 basal 
cells. Scale bars, 10 μM. Example of monopolar spindle with fragmented centrosome stained for 
microtubules (α-tubulin), centrioles (γ-tubulin) and DNA (dapi). T84 cells transfected with wild-type 
CROCC-GFP or (GFP alone see supplementary material for details)  and  immunostained for γ-tubulin (red, 
enlarged in insets). Below on the left, cells transfected with wild-type CROCC and control are maintained in 
neomycin ( g ml-1) for the indicated time. The *P≤0.05, **P<0.01 and  ***P<0.001 were derived from two-
tailed Student’s t-test. Right, chromosome number detected in metaphases (after 5 days) are quantified by 
tetraploid on diploid cells ratio (22 chromosome spreads were analyzed in each condition). The **P<0.01 
was derived from two-tailed Student’s t-test. 
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5 Discussion 
In this study, we have shown that genetic alterations in CROCC are related to a subset of rare  
rhabdoid cancers arising in the colon of adult patients, characterized by a lethal clinical course 
irrespective of stage at diagnosis.  Although these tumors are morphologically indistinguishable 
from their pediatric counterparts, here we show that rhabdoid phenotype arise from distinctive 
pathways, supporting their epithelial origin. The high mutational load further illustrates the biologic 
distinction between RC and pediatric rhabdoid tumors, in which it is well-established the order of 
1–10 mutations per exome reminding a genetic complexity similar to normal cells.60,62,63  Notably, 
we found that RCs share mutation in genes that participate to centrosome and microtubule-
dependent functions, suggesting an alternative route towards aneuploidy and chromosome 
instability. This is particularly relevant because exome data from ~5,000 human cancers indicate 
that genetic alterations in centrosomal genes are relatively rare.1,62,63,41 
            Our data unveil that impaired CROCC activity either caused by somatic mutations or copy 
number loss at the 1p36.13 locus “in a heterozygous state” result in defective centrosomes 
phenotypes without extra centrosomes, gross mitotic errors and increased tetraploidy. In contrast, 
related cancers lacking CROCC alterations “pediatric rhabdoid or prototypical colorectal tumors”, 
display recurrent CROCC overexpression resulting in morphologically normal, larger or 
supernumerary centrosomes.1-4,  How does CROCC facilitate mitotic errors? This gene is essential 
to establishing  and maintaining interconnected centrosome after centrioles disengagement, and its 
phosphorylation by several kinases stimulates premitotic centrosome disjunction  thereby ensuring 
mitotic spindle fidelity. In the RC cases, is conceivable  that defective CROCC could compromise  
its controlled degradation by kinases impairing bipolar mitotic spindle assembly.58  Indeed,  
CROCC knockdown in CRC cells lacking aneuploidy, causes structurally compromised 
centrosomes, monopolar spindle DNA segregation errors, increased formation of micronuclei and 
tetraploid cells. In this respect, tetraploid cells were characterized by stoichiometric double  amount 
of DNA, a larger cell volume miming rhabdoid-like phenotype observed in vivo.  Finally, CROCC 
restoration into cells harboring allele loss at the 1p36.13 locus, further confirmed its critical role as 
biological barrier against replication stress and tetraploidy, both common route to chromosomal 
instability and intratumour heterogeneity.3,67   These findings highlight that genetic aberrations in 
critical centrosomal genes may be of broad general relevance to cancer or be exploited 
therapeutically by cytotoxic or microtubule destabilizing agents72,73. Therefore, in some contexts 
centrosome anomalies “amplification or deletion”, could confer advantageous characteristics that 
promote tumor progression.4,74,75 So far however, mutations in centrosome genes with a critical role 
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in procentriole formation, CEP57, CEP135 and PLK4 kinase, have been only identified in rare 
diseases, particularly microcephaly and Seckel syndrome.71,74  Future experiments will aim to 
determine how centrosome anomalies are connected with pathways such as “TP53, WNT/β-catenin 
or Hippo” that play a key role in safeguarding the integrity of the human genome.   In conclusion, 
the study of rare and lethal human tumors may allow molecular insight into crucial pathways that 
can have profound consequences on cancer cells reprogramming and shape.  
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